B7 immune checkpoint family members as putative therapeutics in autoimmune disease: An updated overview

Int J Rheum Dis. 2022 Mar;25(3):259-271. doi: 10.1111/1756-185X.14273. Epub 2022 Jan 7.

Abstract

Autoimmune diseases, especially among young people in the US, are one of the leading causes of morbidity and death. The immune responses are the fundamental pathogenicity of autoimmune disorders. The equilibrium between stimulatory and inhibitory signals is critical for the stimulation, migration, survival, and T cell-related immune responses. The B7 family can substantially regulate T cell-mediated immune responses. Nevertheless, recent breakthroughs in immune checkpoint blockade in cancer immunotherapy have facilitated autoimmune diseases, especially among the prone populations. In the current study, we tried to concisely review the role of the B7 family in regulating immune reactions and the influence of immune checkpoint inhibitors on autoimmunity development.

Keywords: B7 family checkpoints; autoimmune disease; host immune response; immune checkpoint.

Publication types

  • Review

MeSH terms

  • Autoimmune Diseases / immunology
  • Autoimmune Diseases / therapy*
  • Autoimmunity*
  • B7-H1 Antigen / pharmacology*
  • Humans
  • Immunotherapy / methods*
  • T-Lymphocytes / immunology*

Substances

  • B7-H1 Antigen